VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference
SOUTH SAN FRANCISCO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen), a late clinical-stage, neuro-focused...
Day: March 24, 2022
Piezo Motion’s Precise Motor Technology Is Now Available in Germany
Piezo Motion partnership with MEV Elektronik will deliver motion control and automation solutions to original equipment manufacturers in central and...
OrthoPediatrics Corp. Launches PediFlex™ Advanced Interlock Clamp System
WARSAW, Ind., March 24, 2022 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively...
Sientra Receives Regulatory Approval to Market Breast Implants in Canada
Health Canada approval continues Sientra’s international expansion and growth accelerationSANTA BARBARA, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc....
Longeveron Presents at Second Euro-Geroscience Conference
Longeveron management presents live at the Second Euro-Geroscience Conference and at a pre-meeting task forceMIAMI, March 24, 2022 (GLOBE NEWSWIRE)...
Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021...
BioCardia to Host 2021 Financial Results and Corporate Update Conference Call on March 29, 2022
SUNNYVALE, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results
On Track to Initiate Phase 1 Clinical Trials in Healthy Volunteers for SZN-1326 and SZN-043 in the Third Quarter of...
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2021 and Provides Corporate Update
Building Momentum with Completion of Patient Enrollment in 4 Late-Stage Trials Multiple Late-Stage Clinical Trial Data Catalysts in 2022:– Nyxol®...
ContraFect Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Provides Business Update
Phase 3 DISRUPT study enrollment continues on course towards conducting interim futility analysis as anticipated in H1 2022YONKERS, N.Y., March...
Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update
$36.88 Million in cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash...
KemPharm to Participate in Maxim’s 2022 Virtual Growth Conference
CELEBRATION, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical company focused on the discovery and...
Vanqua Bio to Present at the Stifel 2022 CNS Day Conference
CHICAGO, March 24, 2022 (GLOBE NEWSWIRE) -- Vanqua Bio today announced that the company will participate in the Stifel 2022...
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®
CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical...
Dante Labs establishes the first of its Regional Medical Genomics Boards in Europe made of national and multinational world leaders in genomics
NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) -- Dante Labs, a global leader in genomics and precision medicine, announces the...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty...
Mydecine Receives Conditional IRB Approval for Phase 2b Smoking Cessation Study
Clinical trial programs advance to further assess psychedelic-assisted psychotherapy utilizing lead drug candidate MYCO-001DENVER, March 24, 2022 (GLOBE NEWSWIRE) --...
InflaRx Reports Full Year 2021 Financial and Operating Results
Company received corrected FDA advice letter for Phase III trial with vilobelimab in hidradenitis suppurativaPositive Phase IIa data reported with...
Spectral Announces Fourth Quarter and Fiscal 2021 Results and Corporate Update
TORONTO, March 24, 2022 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic...
Emerging Markets Report: Love Letters
An Emerging Markets Sponsored Commentary ORLANDO, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- In the world of emergent small cap...
